H168
R(+)-7-Hydroxy-DPAT hydrobromide
>98%, solid
Synonym(s):
R(+)-2-Dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide, R(+)-7-Hydroxy(dipropylamino)tetralin hydrobromide
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C16H25NO · HBr
CAS Number:
Molecular Weight:
328.29
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
assay
>98%
form
solid
color
white
solubility
H2O: >100 mg/mL, ethanol: >56 mg/mL
SMILES string
Br.CCCN(CCC)C1CCc2ccc(O)cc2C1
InChI
1S/C16H25NO.BrH/c1-3-9-17(10-4-2)15-7-5-13-6-8-16(18)12-14(13)11-15;/h6,8,12,15,18H,3-5,7,9-11H2,1-2H3;1H
InChI key
ODNDMTWHRYECKX-UHFFFAOYSA-N
Gene Information
human ... DRD3(1814)
Biochem/physiol Actions
Selective D3 dopamine receptor agonist; active enantiomer of (±)-7-hydroxy-DPAT.
Features and Benefits
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Disclaimer
Photosensitive
Storage Class
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
R J Baldessarini et al.
European journal of pharmacology, 239(1-3), 269-270 (1993-08-03)
Racemic 7-hydroxy-N,N-dipropylaminotetralin (7-OH-DPAT) shows greater affinity for limbic-selective dopamine D3 receptors than for more ubiquitous dopamine D2 receptors. R(+)-7-OH-DPAT was prepared and evaluated in radioreceptor assays using membranes of fibroblasts expressing the human dopamine D3 receptor as well as rat
Eriko Ikeda et al.
Molecular pharmacology, 83(5), 959-967 (2013-02-23)
The dopamine D3 receptor (DRD3) in the ventral striatum is thought to influence motivation and motor functions. Although the expression of DRD3 in the ventral striatum has been shown to exhibit 24-hour variations, the mechanisms underlying the variation remain obscure.
Susanne Koschatzky et al.
ChemMedChem, 7(3), 509-514 (2012-01-04)
The neuromodulatory peptide neurotensin has been described to functionally interact with dopaminergic pathways of the human brain. We employed radioligand binding studies to investigate the physical interaction between co-expressed dopamine D(2L) or D₃ and neurotensin NTS₁ or NTS₂ receptors. Substantial